Why the study?
Do atropine and isoproterenol improve cardiac conduction parameters in patients with familial amyloid polyneuropathy?
Do atropine and isoproterenol improve cardiac conduction parameters in patients with familial amyloid polyneuropathy?
Isoproterenol, but not atropine, may have beneficial electrophysiologic effects for treating bradyarrhythmias or conduction blocks in patients with familial amyloid polyneuropathy.
Answers are grounded in this paper and cite their sources.
Isoproterenol may aid conduction parameters in familial amyloid polyneuropathy; leaves open clinical outcome trials.
In ten patients with familial amyloid polyneuropathy (FAP), the effects of atropine and isoproterenol on the cardiac conduction system were studied using surface electrocardiogram (ECG) and His bundle electrograms. Intravenous administration of atropine sulfate, 1 mg, prolonged the sinus cycle length ( SNCL ) in 6 of 8, sinus node recovery time (SNRT) in 3 of 6, automaticity recovery time of the atrioventricular (A-V) node in one, A-H interval in 4 of 7, effective refractory periods of the atrium and A-V node in 4 of 6 and in 3 of 7 patients, respectively. Continuous intravenous administration of isoproterenol, 0.5 micrograms/min, shortened the SNCL , SNRT, A-H interval and refractory periods of the atrium and A-V node in all patients. We conclude that the therapeutic doses of atropine may be useless or potentially detrimental for bradyarrhythmias or conduction blocks in some patients with FAP, but that isoproterenol may have beneficial effects on those arrhythmias in FAP.
No takes yet. Share an insight, caveat, or question.
Horio et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: